Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus chemotherapy with or without thalidomide in first-line advanced non-small cell lung cancer
ChiCTR2400082910Phase 3Not yet recruiting
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of camrelizumab and thalidomide in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Affiliated Hospital of Jiangnan University. Primary endpoints: Reactive cutaneous capillary endothelial proliferation incidence, Objective response rate and 4 more. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
camrelizumabthalidomide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400082910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082910.